The clinical trial showed significant improvement in blood pressure of participants who were given a new catheter-based treatment where blood pressure lowering medication had failed.
Director of Monash University's Centre of Cardiovascular Research and Education in Therapeutics, Professor Henry Krum led the research collaboration between Monash, the Baker Heart and Diabetes Institute, and St Vincent's Hospital to develop the new surgical technique that disrupts nerves around the kidneys to dramatically reduce high blood pressure.
The technique could benefit those at high risk of heart attack or stroke from high blood pressure that resists conventional drug treatments.
Professor Krum presented these data in a late breaking clinical trial session at The American College of Cardiology's 58th Annual Scientific Session earlier this week and was lead author on a simultaneous publication in The Lancet.
The results are set to revolutionise high blood pressure treatment in patients around the world.
Professor Henry Krum said the treatment would benefit those five to twenty per cent of patients with high blood pressure who do not respond to medication.
"Patients who underwent the procedure had a significant reduction in their blood pressure levels and we were able therefore to reduce their risk of severe stroke or heart attack," Professor Krum said.
A total of 50 patients were recruited from Australia and overseas for the trial conducted by a team of researchers, which included Professor Henry Krum, from Monash University, Professor Markus Schlaich and Professor Murray Esler from Baker IDI and Professor Rob Whitbourn from St Vincent's Hospital, Melbourne.
Professor Krum said the trial results were the most significant in the treatment of high blood pressure since the introduction of the drugs that are in use today.
"We showed an excellent safety profile of this brief, catheter-based therapy. No long-term adverse events resulted from the procedure. Therapeutic renal denervation led to a large and persistant decrease in blood pressure, which was achieved in patients resistant to multiple existing hypertensive drug types. Moreover, reduction of blood pressure was evident as early as 1 month, was further reduced at 3 months, and persisted through subsequent assessments," Professor Krum said.
The procedure is carried out under local anaesthetic and uses radio energy frequency, delivered to the targeted nerve area via catheter. As a result the nerves are silenced in the renal artery, which supplies blood to the kidneys.
Researchers had long-believed that this region was a key regulator of blood pressure, but until these trial results the theory had not been successfully trialled.
"The catheter allowed us to target a very specific area to deliver the right amount of frequency to the nerves without damaging the surrounding areas," Professor Krum said.
Samantha Blair | EurekAlert!
Speed data for the brain’s navigation system
06.12.2016 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)
Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
06.12.2016 | Materials Sciences
06.12.2016 | Medical Engineering
06.12.2016 | Power and Electrical Engineering